FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2462783201> ?p ?o ?g. }

• W2462783201 abstract "Abstract In the present analyses, we sought to determine the impact of disease characteristics at diagnosis and at HSCT including pre-transplant MDS therapy and depth of response, stem cell source and intensity of conditioning regimen on disease outcomes after HSCT. Between 2000 and 2012, 291 MDS patients with a median age of 55 years (range, 18-71) were transplanted with a matched related donor (MRD, n=131), matched unrelated donor (MUD, n=114) or mismatched donors (MMD (n=46). The study cohort had high-risk features including 117 patients (40.2%) with therapy-related MDS (tx-MDS) and 78 (27.3%) with MK+. Histological subtype was RAEB-1 and -2 in 122 (41.9%) and CMML in 26 (8.9%) patients. Therapy prior to HSCT was chemotherapy only (chemo, n=81), hypomethylating agents only (HMA, n=100) and both (chemo+HMA, n=50). There were 74 untreated patients prior to HSCT. Of 74, 45 (60.8%) had tx-MDS, 48 (64.9%) had MRD and proceeded with HSCT with a median of 4.7 months. Among different therapy groups; histological subtype and disease status at HSCT, donor type and conditioning intensity were not different (Table 1). The median age among therapy groups were different with 54 vs. 57 and 59 observed in chemo, HMA and chemo+HMA (p<0.001). Compared with chemo and chemo+HMA, HMA had more monosomal karyotype (MK) (40.4% vs. 16% in chemo and 11.4% in chemo+HMA, p<0.001) and higher risk groups by Revised International Prognostic Score (IPSS-R) (58% vs. 40.7% in chemo and 27.8% in chemo+HMA, p=0.006)Table1Demographic of therapy groupsUntreated (%) n=74Chemo (%) n=81HMA (%) n=100Chemo+HMA (%) n=36P*Median age51545759<0.001RAEB-1 and -219 (25.7)41 (50.6)52 (52)15 (41.7)0.1CMML2 (2.7)10 (12.5)9 (9)3 (13.9)0.1MDS-tx45 (60.8)29 (35.8)37 (37)6 (16.7)0.07MK+21 (29.6)13 (16.1)40 (40.4)4 (11.4)<0.001High&very high risk by IPSS-R30 (40.5)33 (40.7)58 (58)10 (27.8)0.006CR at HSCT021 (25.9)25 (25)3 (8.3)0.08MUD/MMD18/8 (24.3/10.8)34/17 (42/21)44/17 (44/17)18/4 (50/11.1)0.8Myeloablative conditioning55 (74.3)56 (69.1)69 (69)21 (58.3)0.5*Comparison was between different therapy groups The median follow-up of 109 survivors was 45 months. There was no difference for EFS between different therapy groups including untreated patients. Disease status of CR vs. more advanced disease at HSCT was not associated with EFS. Even in patients with high or very high risk disease by Revised International Prognostic Scoring System (IPSS-R), EFS was comparable in patients who were transplanted in CR vs. more advanced disease (Figure 1). In multivariate analyses, only MMD and MK were poor prognostic factors. The univariate point estimates at the stated time-points and multivariate outcomes are summarized in the Table1 and 2.Figure 1EFS by previous therapy and disease status at HSCT in patients with high and very high risk disease by IPSS-R.Figure 1. EFS by previous therapy and disease status at HSCT in patients with high and very high risk disease by IPSS-R.Table 2The summary outcomesUntreatedChemoHMAChemo+HMA3 year EFS43.4%31.2%31.1%31.5%3 year relapse incidence21.7%32.3%30.3%29.6%3 year TRM18.8%30.9%32.1%27.%Table 3Multivariate analyses for EFS**EFSVariableHRIpMKCNRefMK-1.81.2-2.70.003MK+4.52.9-7.0<0.001Histology per WHORA/RCMDSRefRAEB1.40.9-2.00.2CMML2.01.1-3.70.03Undifferentiated1.20.8-1.90.4**Adjusted for BM blast count, platelet transfusion, ferritin level and disease status at HSCT, previous MDS therapy and donor type. In summary, MK and histology were the only prognostic factors for EFS in MDS HSCT patients. Therapy prior to HSCT and disease status at HSCT were not found to be prognostic for any disease outcome in our analyses. Our results suggest that high-risk MDS patients should proceed with HSCT without any delay given that more therapy with the goal to achieve better disease control may not lead to more favorable disease outcomes after HSCT. These data need to be confirmed in larger, controlled clinical trials. Disclosures: No relevant conflicts of interest to declare." @default.
• W2462783201 created "2016-07-22" @default.
• W2462783201 creator A5004417292 @default.
• W2462783201 creator A5016928938 @default.
• W2462783201 creator A5034104852 @default.
• W2462783201 creator A5034264716 @default.
• W2462783201 creator A5048913229 @default.
• W2462783201 creator A5049385583 @default.
• W2462783201 creator A5055885795 @default.
• W2462783201 creator A5059138314 @default.
• W2462783201 creator A5061026876 @default.
• W2462783201 creator A5066894053 @default.
• W2462783201 creator A5075342012 @default.
• W2462783201 creator A5085076031 @default.
• W2462783201 creator A5088175930 @default.
• W2462783201 creator A5091083304 @default.
• W2462783201 date "2013-11-15" @default.
• W2462783201 modified "2023-10-15" @default.
• W2462783201 title "Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS" @default.
• W2462783201 doi "https://doi.org/10.1182/blood.v122.21.305.305" @default.
• W2462783201 hasPublicationYear "2013" @default.
• W2462783201 type Work @default.
• W2462783201 sameAs 2462783201 @default.
• W2462783201 citedByCount "1" @default.
• W2462783201 countsByYear W24627832012015 @default.
• W2462783201 crossrefType "journal-article" @default.
• W2462783201 hasAuthorship W2462783201A5004417292 @default.
• W2462783201 hasAuthorship W2462783201A5016928938 @default.
• W2462783201 hasAuthorship W2462783201A5034104852 @default.
• W2462783201 hasAuthorship W2462783201A5034264716 @default.
• W2462783201 hasAuthorship W2462783201A5048913229 @default.
• W2462783201 hasAuthorship W2462783201A5049385583 @default.
• W2462783201 hasAuthorship W2462783201A5055885795 @default.
• W2462783201 hasAuthorship W2462783201A5059138314 @default.
• W2462783201 hasAuthorship W2462783201A5061026876 @default.
• W2462783201 hasAuthorship W2462783201A5066894053 @default.
• W2462783201 hasAuthorship W2462783201A5075342012 @default.
• W2462783201 hasAuthorship W2462783201A5085076031 @default.
• W2462783201 hasAuthorship W2462783201A5088175930 @default.
• W2462783201 hasAuthorship W2462783201A5091083304 @default.
• W2462783201 hasConcept C126322002 @default.
• W2462783201 hasConcept C141071460 @default.
• W2462783201 hasConcept C143998085 @default.
• W2462783201 hasConcept C2776694085 @default.
• W2462783201 hasConcept C2777408962 @default.
• W2462783201 hasConcept C2778336483 @default.
• W2462783201 hasConcept C2781413609 @default.
• W2462783201 hasConcept C2911091166 @default.
• W2462783201 hasConcept C71924100 @default.
• W2462783201 hasConcept C90924648 @default.
• W2462783201 hasConceptScore W2462783201C126322002 @default.
• W2462783201 hasConceptScore W2462783201C141071460 @default.
• W2462783201 hasConceptScore W2462783201C143998085 @default.
• W2462783201 hasConceptScore W2462783201C2776694085 @default.
• W2462783201 hasConceptScore W2462783201C2777408962 @default.
• W2462783201 hasConceptScore W2462783201C2778336483 @default.
• W2462783201 hasConceptScore W2462783201C2781413609 @default.
• W2462783201 hasConceptScore W2462783201C2911091166 @default.
• W2462783201 hasConceptScore W2462783201C71924100 @default.
• W2462783201 hasConceptScore W2462783201C90924648 @default.
• W2462783201 hasLocation W24627832011 @default.
• W2462783201 hasOpenAccess W2462783201 @default.
• W2462783201 hasPrimaryLocation W24627832011 @default.
• W2462783201 isParatext "false" @default.
• W2462783201 isRetracted "false" @default.
• W2462783201 magId "2462783201" @default.
• W2462783201 workType "article" @default.